Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group has announced a leadership reshuffle effective 19 December 2025, with long-serving executive director Zhang Cuilong stepping down from his roles as vice-chairman, chief executive officer and authorised representative due to work reassignment, while remaining on the board. The company has appointed Cai Lei, currently executive president and head of overseas R&D and pharmaceutical product sales, as vice-chairman, executive director, CEO and authorised representative, and named Wei Qingjei as vice-chairman, executive director and chief operating officer, moves that underscore a tighter alignment of top management with CSPC’s international research and sales strategy and reinforce the influence of the founding Cai family in the group’s governance.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products, with an expanding focus on overseas R&D and international sales through its subsidiaries and specialized business divisions.
Average Trading Volume: 121,701,023
Technical Sentiment Signal: Buy
Current Market Cap: HK$86.5B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.